There is considerable concern regarding the transforming potential of retroviral vectors currently used for gene therapy, with evidence that retroviral integration can lead to leukemia in recipients of gene-modified stem cells. However, it is not clear whether retroviral-mediated transduction of T cells can lead to malignancy. We transduced mouse T cells with a Moloney murine retroviral gene construct and transferred them into congenic mice, which were preconditioned to enhance the engraftment of transferred T cells. Recipients were then observed long-term for evidence of cancer. Transferred T cells persisted in mice throughout life at levels up to 17% with gene copy numbers up to 5.89 Â 10 5 per million splenocytes. Mice receiving gene-modified T cells developed tumors at a similar rate as control mice that did not receive T cells, and tumors in both groups of mice were of a similar range of histologies. Hematological malignancies comprised approximately 60% of cancers, and the remaining cancers consisted largely of carcinomas. Importantly, the incidence of lymphomas was similar in both groups of mice, and no lymphomas were found to be of donor T-cell origin. This study indicates that the use of retroviral vectors to transduce T cells does not lead to malignant transformation.
Introduction
Transduction using retroviral vectors is currently an important option for stable genetic modification of primary cells for gene therapy applications. 1 Retroviral vectors have been used in mouse models of disease to correct deficiencies in genes including those encoding Factor IX for hemophilia, 2,3 g-globin for b-thalassemia [4] [5] [6] and the cytokine receptor common g-chain for severe combined immunodeficiency (SCID). 7 In addition, retrovirus has been used widely to transduce tumor cells and immune cells for cancer therapy. [8] [9] [10] Retroviral vectors have also been used successfully in human trials to correct gene deficiencies in diseases including ADA-SCID, [11] [12] [13] [14] X-linked SCID 15, 16 and chronic granulomatous disease. 17 Retroviruses insert their genes in a semirandom manner into host chromosomes, 18 and it is thought that retroviruses may integrate preferentially into transcriptionally active sites. 19 There is therefore potential to dysregulate expression of genes including proto-oncogenes, which may lead to malignant transformation of gene-modified cells.
There is increasing evidence from mouse studies that retroviral transduction of stem cell populations can lead to increased proliferation or transformation resulting in malignancy. Genomic insertion of marker genes in mouse bone marrow stem cells has resulted in the production of immortalized cell lines in vitro 20 and can produce nonmalignant clonal expansion of hematopoietic stem cells in vivo. 21 Deregulation of cell growth can also proceed further following retroviral transduction, leading to transformation and malignancy following the use of retroviral vectors encoding oncogenes or growth factors, [22] [23] [24] and the location of viral insertion was thought to play a role in the transforming process. There is also evidence that vectors encoding a marker gene, truncated nerve growth factor receptor, can also lead to leukemia, 25 although other studies have not found this to be the case. 26 Of greatest concern are observations that retroviral transduction of hematologic stem cells can lead to malignancy in primates and humans. Transduction of Rhesus macaque CD34 + stem cells with a gene encoding drug resistance led to acute myeloid leukemia in one of seven animals after drug administration. 27 Leukemia or T-cell monoclonality was also observed in 4 of 11 patients who received CD34 + bone marrow cells gene-modified with a retroviral vector encoding the common g-chain of the interleukin-2 receptor (gc) [28] [29] [30] Vector insertion near the proto-oncogene LMO2 was thought to have played a role in cell transformation in these patients.
In contrast to the case in gene-modified hematopoietic stem cells, there is no evidence of transformation following transduction of T cells. However, with the exception of gene-modified virus-specific T cells in patients, 31, 32 there has not been long-term follow-up of recipients in human or animal systems in which genemodified T cells were demonstrated to persist for several years. To investigate the issue of potential transforming ability of retroviral vectors in T cells, we performed adoptive transfer in mice and determined the incidence of cancer formation over their entire lifespan.
The gene used to modify T cells in this study encoded a chimeric T-body for redirection of T-cell activity against the tumor-associated antigen, Lewis-Y (Le Y ). The T-body is composed of extracellular single-chain antibody, specific for Le Y , linked to the intracellular signaling regions of CD28 and CD3-zeta. 33, 34 To facilitate T-cell engraftment, mice received non-myeloablative conditioning by means of whole-body irradiation (2.5 Gy). The resulting immunodepletion is similar to that observed in patients by using chemotherapy or irradiation before adoptive immunotherapy.
This report describes the first long-term study of mice that have received retrovirally gene-modified T cells and demonstrates that transduction with this Moloney murine leukemia virus-based vector does not lead to T-cell transformation.
Results

Characterization of gene-modified Le Y -specific T cells
To determine the level of transduction following incubation with the retroviral vector, T cells were subjected to flow cytometric analysis after staining with a monoclonal antibody specific for the idiotype of the anti-Le Y receptor. Approximately 22% of T cells were demonstrated to express the anti-Le Y receptor (Figure 1a ). To ascertain whether expression of the chimeric receptor could enable a T-cell response against Le Y+ tumor cells, the ability of T cells to secrete interferon-g following incubation with Le Y+ tumor cells was determined using enzyme-linked immunosorbant assay. Interferon-g secretion was detected specifically in response to Le Y+ target cells and not in response to cells lacking Le Y expression (Figure 1b ). Immobilized anti-CD3 and anti-CD28 served as a positive control for T cell triggering through the endogenous T-cell receptor.
Tumor incidence is similar in T-cell recipients and control mice Following irradiation and T-cell transfer, both T-cell recipient (n ¼ 25) and control (n ¼ 14) groups of mice were observed and were euthanized when tumor formation became apparent or when moribund. There was no significant difference in survival between the two groups of mice over the observation period exceeding 2 years (P2 ¼ 0.72, Fisher's exact test) (Figure 2a) . The mean survival time of mice receiving T cells did not differ significantly from control mice (P2 ¼ 0.99, MannWhitney test) (Figure 2b ). There was no significant impact of gene-modified T cells on the rate of tumor onset. In addition, the overall incidence of tumors in T-cell recipient mice (92%) was similar to that in control mice (100%). Interestingly, tumor incidence in these mice exceeded that normally observed in wild-type mice, which can vary from 25 to 75% depending on the mouse strain and maintenance. [35] [36] [37] This increase may have been due to the prior radiological conditioning given to mice.
A similar spectrum of tumors arises in T-cell-treated and control mice Although transfer of gene-modified T cells did not impact significantly on the incidence or rate of tumor formation in mice, it still remained possible that the incidence of different types of tumor, in particular lymphoma, varied between the groups. To investigate Absence of retroviral transformation of T cells in mice JA Westwood et al this question, tissues were taken after euthanasia and subjected to a series of analyses as outlined briefly in Figure 3 and in detail in the following sections. The first analysis involved histological examination of hematoxylin and eosin-stained formalin-fixed sections. The histological diagnoses for mice in groups 1 and 2 are summarized in Tables 1 and 2 . Histopathological analysis showed that many of the tumors were of epithelial origin and thus originating from the host mouse, but not from the adoptively transferred anti-Le Y T cells (no gene-modified epithelial cells were injected); in group 1 mice (receiving T cells), 40% (10/25) succumbed specifically to carcinomas, sarcomas, cysts or hemangiomas, which was similar to the incidence of 43% (6/14) in group 2 (Tables 1 and 2 ). Interestingly, a diverse range of tumor types originated spontaneously in these mice including carcinomas of the ovary, breast, lung and salivary gland (Table 1; Figure 4 ).
Characterization of lymphomas in mice receiving gene-modified T cells
The most relevant type of malignancy that could arise from gene-modified T cells was lymphoma, and so we next focused our attention on this class of cancers. The incidence of lymphoma was similar in both groups: 60% (15/25) in group 1 and 57% (8/14) in group 2. This suggested that gene-modified T cells did not contribute greatly to lymphoma incidence; however, it still remained possible that a proportion of lymphomas arose from transferred T cells. Therefore, further analyses of lymphomas in group 1 (T-cell recipient) mice were performed. Flow cytometry was used on freshly dissociated grossly enlarged or atypical lymphoid tissue to determine whether it was composed predominantly of cells of recipient origin (CD45.2 + ) or donor origin (CD45.1 + ). Reasoning that malignant cells would be expected to comprise a significant proportion of tumorinvolved lymphoid tissue, we designated any tumors containing less than 10% CD45.1 + cells to be of recipient origin. Of the 15 lymphomas in mice receiving genemodified T cells, 9 were designated as of recipient origin based on this criterion (Table 3) . Tissues from the remaining six mice were subjected to further analysis.
Lymphomas arising after serial passage into mice were CD45.2 + To gain insight into the origin of the malignant cells taken from the remaining six mice, cryopreserved cells from lymphoid tissue were passaged into a second group of BALB/c mice (that were not pre-conditioned using irradiation). Of the six lymphomas passaged, four gave rise to lymphomas in a proportion of the recipients, as indicated by morbidity and enlarged lymphoid tissue including splenomegaly. When spleens were analyzed using specific antibodies and flow cytometry, the predominant cell type was demonstrated to be CD45. Absence of retroviral transformation of T cells in mice JA Westwood et al 42 were not derived from adoptively transferred genemodified T cells, but were of recipient origin.
Immunohistochemical staining of tissues
Serial passage of tumor cells from two mice (mice 28 and 31) failed to produce tumors in secondary recipient mice. To determine the origin of the malignant cell type in these mice, frozen tissue sections were analyzed using immunohistochemistry following staining with antibodies specific for CD45.1, CD45.
2, CD3 (T cells), B220 (B cells) and F4/80 (monocyte/macrophage).
Histological analysis demonstrated that the lymphomas were of CD45.2 recipient-derived and not originating from the adoptively transferred T cells (Table 4) .
Persistence of adoptively transferred T cells in mice
Having demonstrated that gene-modified T cells did not become malignant, it was of interest to determine the level of persistence of transduced T cells in recipient mice. Clearly, CD45.1 + T cells persisted in the majority of recipients until the time of their death, varying from 1.9 to 16.7% of the total cells in the spleen (Figure 5a ). For some mice, the T cells persisted for over 2 years. However, as only a proportion of T cells in the original Absence of retroviral transformation of T cells in mice JA Westwood et al
CD45.1
+ -injected population were transduced, we determined the relative copy number of the transgene in spleens to estimate the degree of persistence specifically of gene-modified T cells using qPCR. Molecular analysis was used rather than flow cytometry, because the number of integration events in a cell population is more relevant to the transforming potential of the transgene. Transgene was detected in spleens of 96% of To gain further insight into the kinetics of T-cell engraftment and persistence, we performed a second experiment in which mice received transduced T cells, with or without prior conditioning by irradiation, and determined the level of T cells in peripheral blood in the short-to-medium term after cell transfer. T cells transferred into non-irradiated mice peaked in numbers 2 days after injection and then quickly declined to reach a level of approximately 1% of circulating leukocytes for the remaining 5 months of the observation period ( Figure  5d ). In contrast, when transferred into irradiated mice, T cells reached higher proportions of circulating leukocytes by 3 days after transfer, and then became established to levels of approximately 10% over the succeeding months. The rapid capacity of T cells to reach levels of 5-10%, which were similar to those seen at later time points in the group of mice monitored for tumor formation, suggested that this level is associated with normal engraftment of transferred T cells in conditioned mice, rather than an excessively high level associated with malignancy.
Discussion
In this study, mice receiving T cells gene-modified with a retroviral vector developed cancers at a similar rate and incidence as control mice that did not receive T cells. In addition, the frequency of various types of tumors, including lymphoma, arising in both groups of mice was similar. These data suggested that transferred T cells did not contribute to malignancy. A series of tests, involving flow cytometry, immunohistochemistry and serial passage of lymphomas in mice, confirmed that no malignancies arose from the infused gene-modified T cells, despite their persistence for the lifetime of almost every mouse.
We demonstrated that, following adoptive transfer into preconditioned mice, T cells quickly become established at between 2 and 17% of leukocytes and persist at approximately these levels throughout their life without undergoing transformation. The mean value of transferred T-cell engraftment (determined at death) was 7.2%, and with an estimated 2-3 Â 10 8 leukocytes in a mouse, it was apparent that in some mice, the adoptively transferred T cells did expand from the injected 1 Â 10 7 . This likely occurred through normal homeostatic mechanisms in the lymphodepleted environment of irradiation-conditioned mice. Transduced T cells made up approximately 20% of the cells initially injected, and clearly some of these cells persisted throughout the life of the mice, as the transgene could be detected in genomic DNA from splenocytes using quantitative PCR. However, the actual number of transduced cells persisting was not clear, as the copy number of the transgene per cell after extended time in mice was not known. Some investigators have previously estimated between 1 and 10 copies per cell following the use of retroviral vectors to modify T cells. 38, 39 Nevertheless, we consider the frequency of transgene in the leukocyte population to closely represent the potential for transformation.
No T-cell receptor Vb monoclonal CD45.1 + T-cell population was found in any mice for which cryopreserved samples were available (including all mice with hematologic malignancy), thereby indicating that there was no CD45.1 + malignancy in those mice. Cryopreserved splenocytes were not available for two mice, but it was unlikely that transformed CD45.1 + cells were Tissues were cut sequentially and stained with antibodies specific for CD45.1, CD45.2, CD3 (T cell), B220 (B cell) and F4/80 (macrophage), and a histological assessment performed to determine the origin of the lymphoma. 
Absence of retroviral transformation of T cells in mice
JA Westwood et al present in these mice, as one died of a non-malignant disorder (hemangioma) and the other died from lung adenocarcinoma. Interestingly, the relative proportions of individual Vb subtypes varied between individual mice, but it was not clear whether this was related to vector integration or random variation. It is noteworthy that some mice, in particular mice 19 and 42, had unusually high percentages of individual Vb subtypes, namely Vb14 and Vb7, respectively. In addition, there was a correlation between transgene copy number and age of mice. Taken together, these data suggest that, despite the absence of frankly malignant CD45.1 + T cells, there may be a preferential expansion of some clones, but it is unknown whether this is associated with transduction or is simply due to aging or variations in health of individual mice.
The dose of T cells in this mouse study was chosen to approximate the equivalent dose given to humans. In this study, the T-cell dose was 1 Â 10 7 cells per mouse, 20% of which expressed the transgene. Therefore, each 20 g mouse received approximately 2 Â 10 6 transduced T cells (1 Â 10 8 cells kg
À1
), which is comparable to the dose per kg of gene-modified T cells given to patients. 10, 40, 41 However, the absolute number of genemodified T cells was considerably less than that used in the clinic. Thus, although there is evidence that there can be close agreement between the transforming potential of retroviral vectors in mouse and human stem cells despite the delivery of much reduced absolute numbers of transduced stem cells in mice, 22, 28 it should be noted that this may not be the case when considering T cells. Although mice were only followed for a little over two years in this study, inference to longer periods in humans may be gained from these data, as mice have accelerated developmental/aging and metabolic processes. For example, although leukemia was not observed in gc-deficient humans receiving gc-gene-modified stem cells until almost 3 years later, 28 gc-deficient mice developed lymphoma 6 months to 1 year after gc-genemodified stem cell transplant. 22 In addition, mice can develop a wide range of cancers within 2 years, that do not develop in humans until much later. Thus, a 2-year period of observation in mice may represent a longer period in humans.
Mice received non-myeloablative conditioning before cell transfer to approximate the preconditioning sometimes given to patients before adoptive immunotherapy. 42 A pre-transfer conditioning regimen results in enhanced levels of transferred cells in the circulation, and their increased persistence for many months. There are several hypotheses as to why this happens, including the increased availability of cytokines, which can act as growth factors, and the removal of regulatory cells that would otherwise inhibit engraftment of large numbers. 43, 44 The conditioning regimen used in the present study provided a stringent test of the transforming potential of retroviral vectors in T cells, as it enabled long-term persistence of large numbers of transduced T cells, thereby providing ample opportunity for transformation either as a direct result of vector integration, or in combination with other oncogenic events.
This study was necessarily done in mice without preexisting tumors (to ensure long-term survival) and without expression of the tumor-associated antigen on self tissue (as Le Y is not expressed in mice). It is possible that, if Le Y antigen had been present, as it would be in patients, the repeated triggering of the chimeric T body may chronically activate or tolerize T cells, which may influence any oncogenic signal from vector insertion to amplify or decrease the transforming potential. However, this study also serves as a model for other retrovirally mediated gene therapy applications where cell surface receptors may not be used and no cellular activation is associated with the transgene. Indeed, most gene therapy applications probably fall into this latter category.
Finally, no vector integration site analysis was performed on cells from these mice, as gene-modified cells formed polyclonal T-cell populations in mice. Thus, although integration site analysis can provide interesting data when malignancy arises from genetic modification, 45 it was unlikely to provide any meaningful data from the polyclonal populations of T cells in this study, as there would likely be many sites involved consistent with the largely random integration of retroviral vectors. 18 To realize the promise of gene therapy for the treatment of many diseases and disorders, there is a need for vectors with a demonstrated safety record for each particular application. We have demonstrated that despite the potential of Moloney murine leukemia virusbased vectors to lead to transformation of stem cell progeny in mice and humans, these vectors can be used with relative safety to genetically modify mature T cells. This first long-term study in mice supports the utility of mouse models to investigate this question and supports the safety of this type of vector for use in modifying T cells for clinical application.
Materials and methods
Retroviral vector production
The chimeric gene was composed of extracellular singlechain anti-Le Y , [46] [47] [48] linked to the hinge region of CD8 followed by the transmembrane and cytoplasmic domains of CD28 and the cytoplasmic portion of CD3-z. 49 The gene was incorporated into the Moloney murine leukemia virus-based plasmid, pSAMEN. 50 A retroviral producer cell line was generated by transduction of the 3T3-derived GP+E86 cell line 51 using supernatant from a PA317 producer cell line, as described previously. 49 
T-cell transduction and adoptive transfer
Mouse splenocytes were isolated from CD45.1 + . BALB/ c-ptprc a mice (10-17 weeks old) and transduced, as described previously. 34 Briefly, spleens were crushed and erythrocytes were lysed, then passed over nylon wool columns (Polysciences, Warrington, PA, USA) to enrich for T cells. A total of 1 Â 10 7 cells were then stimulated with phytohemagglutinin (2.5 mg ml injection of T cells, mice received conditioning consisting of 2.5 Gy whole-body irradiation, to produce a lymphopenic environment similar to that expected in patients receiving non-myeloablative conditioning prior to adoptive immunotherapy. Another group of 14 BALB/c mice received conditioning, but no T cells. These mice served as controls to discern the contribution of gene-modified T cells to spontaneous cancer incidence.
Flow cytometry and cytokine secretion assay
Expression of the chimeric receptor on the anti-Le Y T cells prior to adoptive transfer was determined by staining with a mouse monoclonal antibody specific for the idiotype of the scFv, LMH-3 IgG1 anti-3S193 idiotype 52 (supplied by Ludwig Institute for Cancer Research), followed by phycoerythrin-conjugated anti-mouse immunoglobulin F(ab 0 ) 2 (Chemicon, Boronia, Australia). Cells were analyzed on a flow cytometer (FacsCalibur, Becton Dickinson, San Jose, CA, USA) using CELLQuest software. Further staining of freshly harvested cells and tissues from mice during the course of the study was performed using antibodies specific for CD45.1 and CD45.2 (FITC-conjugated from BD Biosciences, San Jose, CA, USA). Spleens and lymph nodes were crushed in 5 ml phosphate-buffered saline, and erythrocytes lysed before analysis. For T-cell receptor Vb analysis, cryopreserved splenocytes were thawed, washed and stained with phycoerythrin-conjugated anti-CD45.1 and a panel of FITC-conjugated anti-Vb monoclonal antibodies according to manufacturer's instructions (BD Biosciences, Cat no. 557004) before flow cytometric analysis.
An assay of anti-Le Y T-cell anti-tumor response prior to adoptive transfer was determined for interferon-g secretion using enzyme-linked immunosorbant assay of supernatants from overnight co-culture of 1 Â 
Observations of mice and tissue processing
Mice were observed for greater than 2 years for signs of illness or tumor formation. The mice were examined 2-3 times per week for any behavioral and health changes. Mice were killed by cervical dislocation and a necropsy performed when they became moribund, as defined by symptoms including one or more of the following: lethargy, ruffled fur, abdominal distension, lump, paralysis or cachexia. Gross abnormalities were noted at necropsy. Enlarged or otherwise abnormal organs were removed and a portion fixed in neutral buffered formalin and the remainder frozen in Tissue-Tek O.C.T. compound (Sakura, Tokyo, Japan), for histological processing. Cells from lymphoid organs were also cryopreserved in liquid nitrogen in 10% DMS0.
Histology and immunohistochemistry
Tumors and mouse organs were fixed in 10% neutral formalin, paraffin embedded, processed and stained with hematoxylin and eosin, and the histology assessed by a pathologist in a blinded manner. Images were acquired using Spot.4.6 software, a Spot RT3 camera (Diagnostic Instruments, Sterling Heights, MI, USA) and an Olympus BX51 microscope fitted with a UPlanAPO Â 40 objective, NA ¼ 0.85. Figures were prepared from images transferred through Adobe Photoshop and CorelDraw without manipulation. All immunohistochemistry was performed on frozen sections. Sections were cut from frozen tissues of some mice in group 1 diagnosed with lymphoma (by hematoxylin and eosin). These sections were stained with antibodies specific for CD45.1 and CD45.2, T, B and macrophage markers. Frozen tissues were stained with CD45.1-biotinylated and CD45.2-biotinylated (BD Biosciences), followed by strepavidin-horseradish peroxidase (K0675; Dako, Glostrup, Denmark). T cells were detected using purified rabbit anti-human CD3 (also reacts with mouse CD3) (Lab Vision, Fremont, CA, USA) or the control of pre-immune rabbit sera, followed by anti-rabbit Envision+ horseradish peroxidase (Dako). B cells were detected using purified rat anti-mouse B220 (BD Biosciences) or the isotype control-purified rat IgG2a (BD Biosciences), followed by biotinylated polyclonal goat anti-rat Ig (BD Biosciences) and strepavidin horseradish peroxidase (Dako). Macrophages were stained with affinity-purified anti-mouse F4/80 antigen-pan macrophage marker BM8 (eBioscience, San Diego, CA, USA) followed by biotinylated polyclonal anti-rat Ig (BD Biosciences) and strepavidin horseradish peroxidase. Briefly, sections were brought to room temperature and dried for 20 min before fixing in 95% ethanol for 10 min. Slides were washed in 50 mM Tris-HCl and endogenous peroxidase blocked by incubation in 3% hydrogen peroxide for 10 min and the primary antibody was then applied for 30 min. The detection system was then applied: 30 min for Envision+ detection or 10 min for a biotinylated secondary, followed by 10 min with streptavidin. The chromogen, DAB+ (K3468, Dako) was applied for 10 min. Slides were counterstained with hematoxylin before clearing and mounting.
Lymphoid tumor passage in mice
In some instances of lymphoma (those with greater than 10% CD45.1 + cells in one or more tissues) stored frozen cells were thawed and 4 Â 10 , splenocytes) were injected intravenously on the same day following irradiation. Another group of 12 BALB/c mice received T cells without prior irradiation. Blood was sampled periodically from the retro-orbital sinus from groups of three mice. Erythrocytes were lysed, and leukocytes were stained with FITC-conjugated antibody specific for CD45.1 prior to flow cytometric analysis.
Quantitative PCR
The copy number of Le Y transgene in spleen samples was measured using qPCR incorporating Taqman chemistry (Applied Biosystems, Foster City, CA, USA). Genomic DNA was isolated by lysing cells (1 Â 10 6 ml À1 0 . Reaction tubes contained a total of 25 ml of which 10 ml was cell lysate. Mouse splenocytes containing known percentages of a cell line containing one copy of the retroviral vector were used to generate a standard curve from which the cycle threshold value of samples could be used to determine the gene copy number per million cells.
